Decitabine (CPB 0868, reviewed 2026-06-10)
Summary
Aetna considers decitabine medically necessary for accelerated or blast phase myeloproliferative neoplasm, acute myeloid leukemia, blastic plasmacytoid dendritic cell neoplasm when used with venetoclax, classic Hodgkin lymphoma when used with pembrolizumab and refractory to at least three prior lines of therapy, myelodysplastic syndromes, and myelodysplastic syndrome/myeloproliferative neoplasm overlap neoplasms. Continuation of decitabine is considered medically necessary for those indications when there is no evidence of unacceptable toxicity or disease progression on the current regimen. Aetna considers decitabine experimental, investigational, or unproven for all other indications, including colon, lung, melanoma, ovarian and other solid tumors, multiple myeloma, sickle cell disease, and use in combination with azacitidine.
Get alerts when payers change rules like this one
We check Aetna and other payers every day and email you when a change matches your specialty and state.